| dbo:abstract |
ديفيد إي. نيكولز (بالإنجليزية: David E. Nichols) هو كيميائي أمريكي، ولد في 23 ديسمبر 1944 في كوفينغتون في الولايات المتحدة. (ar) David Earl Nichols (born December 23, 1944, Covington, Kentucky) is an American pharmacologist and medicinal chemist. Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the method that is used to make the optical isomers of hallucinogenic amphetamines. His contributions include the synthesis and reporting of escaline, LSZ, 6-APB, 2C-I-NBOMe and other NBOMe variants (NBOMe-2C-B, NBOMe-2C-C, NBOMe-2C-D), and several others, as well as the coining of the term "entactogen". He is the founding president of the Heffter Research Institute, named after German chemist and pharmacologist Arthur Heffter, who first discovered that mescaline was the active component in the peyote cactus. In 2004 he was named the Irwin H. Page Lecturer by the former International Serotonin Club (now the International Society for Serotonin Research), and delivered an address in Portugal titled, "35 years studying psychedelics: what a long strange trip it's been." Among pharmacologists, he is considered to be one of the world's top experts on psychedelics. Nichols's other professional activities include teaching medicinal chemistry and molecular pharmacology at Purdue University in West Lafayette, IN, and teaching medical students at the Indiana University School of Medicine. He officially retired in 2012 but has continued to work for the simple reason that nobody is in the position to continue his work and he is considering writing an autobiography. He is currently an adjunct professor at the UNC Eshelman School of Pharmacy, Chapel Hill, NC. (en) David E. Nichols, né le 23 décembre 1944, est un pharmacologue et chimiste en médecine américain. (fr) デヴィッド・アール・ニコルズ（David Earl Nichols、1944年12月23日 - ）は、アメリカ合衆国の医薬化学者、薬理学者である。 1969年以来、向精神薬の分野に取り組んできた。元パデュー大学・薬理学 Robert C. & Charlotte P. Anderson 著名学長。大学院生の頃、幻覚性のの光学異性体の生成に使う方法の特許を取得した。エスカリン、、、や他のNBOMeシリーズ（、NBOMe-2C-C、）の合成と報告に貢献したほか、という言葉を造語した。 ニコルズは、ヘフター調査研究所の創設所長である。研究所の名前は、ペヨーテ・サボテン中から活性成分のメスカリンを初めて発見した薬理学者のに由来する。 2004年には、国際セロトニンクラブよりアーウィン・H・ページ講師に任命されたし、ポルトガルでは「35年の幻覚剤の研究:長く奇妙なトリップ」と題された講演を行った。薬理学者の間で、世界的に有数の幻覚剤の専門家とみなされている。ニコルズの他の専門的な活動は、インディアナ州ウェストラファイエットのパデュー大学にて医薬化学と分子薬理学の教授であったことや、で医学生に講義することであった。 (ja) |
| dbo:academicDiscipline |
dbr:Pharmacology |
| dbo:birthDate |
1944-12-23 (xsd:date) |
| dbo:birthPlace |
dbr:Covington,_Kentucky |
| dbo:institution |
dbr:Purdue_University dbr:Indiana_University_School_of_Medicine |
| dbo:knownFor |
dbr:MDMA dbr:5-HT2A_receptor dbr:Dopamine_receptors dbr:Structure–activity_relationship dbr:MDMA_neurotoxicity |
| dbo:wikiPageExternalLink |
http://www.heffter.org/docs/hrireview/02/chap6.pdf https://www.youtube.com/watch%3Fv=64zZqkKLUGs https://www.youtube.com/watch%3Fv=LbUGRcuA16E http://www.heffter.org/ http://www.heffter.org/docs/hrireview/01/chapter5.pdf http://vimeo.com/16782003 https://web.archive.org/web/20100421072139/http:/www.mcmp.purdue.edu/faculty/%3Fuid=drdave http://www.erowid.org/culture/characters/nichols_david/nichols_david.shtml |
| dbo:wikiPageID |
1396903 (xsd:integer) |
| dbo:wikiPageLength |
9509 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1117250499 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:4-methylthioamphetamine dbr:Psilocybin dbr:Psychedelics dbr:Psychoactive dbr:Purdue_University dbr:Schizophrenia dbr:Designer_drug dbr:Jonathan_Ott dbr:Pharmacology dbr:Rick_Strassman dbr:University_of_Cincinnati dbr:University_of_Iowa dbr:Dopamine_receptor_D1 dbc:Living_people dbr:Covington,_Kentucky dbr:Radioligand dbr:Germany dbr:Ligand dbr:Lysergic_acid_2,4-dimethylazetidide dbr:MDAI dbr:MDMA dbr:2,5-Dimethoxy-4-iodoamphetamine dbr:Bachelor_of_Science dbc:1944_births dbc:Purdue_University_faculty dbc:University_of_Iowa_alumni dbr:Bromo-DragonFLY dbc:Indiana_University_faculty dbr:Heffter_Research_Institute dbr:25I-NBOMe dbr:3,4-Methylenedioxyamphetamine dbr:6-APB dbr:AL-LAD dbr:Alexander_Shulgin dbr:Americans dbr:Amphetamines dbr:5-HT2A_receptor dbr:ETH-LAD dbr:Escaline dbr:PIHKAL dbr:PRO-LAD dbr:Parkinson's_disease dbr:Grey_market dbr:Isomers dbr:Hallucinogens dbc:University_of_Cincinnati_alumni dbc:21st-century_American_chemists dbc:Psychedelic_drug_researchers dbc:American_pharmacologists dbr:LSD dbr:TCB-2 dbr:TiHKAL dbr:Dihydrexidine dbr:Dinapsoline dbr:Dinoxyline dbr:Dopamine dbr:Dopamine_receptors dbr:Arthur_Heffter dbr:PhD dbr:Entactogen dbr:Indiana_University_School_of_Medicine dbr:Mescaline dbr:Casey_William_Hardison dbr:Serotonin dbr:Structure–activity_relationship dbr:Peyote dbr:NBOMe-2C-D dbr:MDMA_neurotoxicity dbr:West_Lafayette,_IN dbr:LSZ dbr:Psychedelics,_dissociatives_and_deliriants dbr:Structure-activity_relationship dbr:Pharmacologist dbr:Postdoc dbr:3-Methyl-4,5-methylenedioxyamphetamine dbr:4-MTA dbr:2C-I-NBOMe dbr:NBOMe-2C-B dbr:NBOMe-2C-C dbr:Medicinal_chemist |
| dbp:birthDate |
1944-12-23 (xsd:date) |
| dbp:birthPlace |
dbr:Covington,_Kentucky |
| dbp:citizenship |
USA (en) |
| dbp:fields |
Medicinal chemistry, Pharmacology (en) |
| dbp:knownFor |
Extensive research into 5-HT2A receptor and dopamine receptors, SAR of hallucinogens, research into MDMA neurotoxicity and MDMA analogues (en) |
| dbp:name |
David Earl Nichols (en) |
| dbp:residence |
USA (en) |
| dbp:wikiPageUsesTemplate |
dbt:Authority_control dbt:Better_source_needed dbt:Div_col dbt:Div_col_end dbt:Reflist dbt:Short_description dbt:Birth_date_and_age dbt:Infobox_scientist |
| dbp:workplaces |
dbr:Purdue_University dbr:Indiana_University_School_of_Medicine |
| dcterms:subject |
dbc:Living_people dbc:1944_births dbc:Purdue_University_faculty dbc:University_of_Iowa_alumni dbc:Indiana_University_faculty dbc:University_of_Cincinnati_alumni dbc:21st-century_American_chemists dbc:Psychedelic_drug_researchers dbc:American_pharmacologists |
| gold:hypernym |
dbr:Pharmacologist |
| rdf:type |
owl:Thing foaf:Person dbo:Person dul:NaturalPerson wikidata:Q19088 wikidata:Q215627 wikidata:Q5 wikidata:Q729 yago:WikicatAmericanChemists yago:WikicatAmericanPharmacologists dbo:Animal dbo:Eukaryote dbo:Scientist dbo:Species schema:Person yago:WikicatLivingPeople wikidata:Q901 yago:Adult109605289 yago:Advocate109774783 yago:CausalAgent100007347 yago:Chemist109913824 yago:HealthProfessional110165109 yago:LivingThing100004258 yago:Object100002684 yago:Organism100004475 yago:Person100007846 yago:Pharmacist110421470 yago:Pharmacologist110421753 yago:PhysicalEntity100001930 yago:Professional110480253 yago:ResearchWorker110523076 yago:YagoLegalActor yago:YagoLegalActorGeo yago:Scientist110560637 yago:Whole100003553 yago:WikicatPsychedelicDrugAdvocates yago:WikicatPsychedelicResearchers umbel-rc:Scientist |
| rdfs:comment |
ديفيد إي. نيكولز (بالإنجليزية: David E. Nichols) هو كيميائي أمريكي، ولد في 23 ديسمبر 1944 في كوفينغتون في الولايات المتحدة. (ar) David E. Nichols, né le 23 décembre 1944, est un pharmacologue et chimiste en médecine américain. (fr) デヴィッド・アール・ニコルズ（David Earl Nichols、1944年12月23日 - ）は、アメリカ合衆国の医薬化学者、薬理学者である。 1969年以来、向精神薬の分野に取り組んできた。元パデュー大学・薬理学 Robert C. & Charlotte P. Anderson 著名学長。大学院生の頃、幻覚性のの光学異性体の生成に使う方法の特許を取得した。エスカリン、、、や他のNBOMeシリーズ（、NBOMe-2C-C、）の合成と報告に貢献したほか、という言葉を造語した。 ニコルズは、ヘフター調査研究所の創設所長である。研究所の名前は、ペヨーテ・サボテン中から活性成分のメスカリンを初めて発見した薬理学者のに由来する。 2004年には、国際セロトニンクラブよりアーウィン・H・ページ講師に任命されたし、ポルトガルでは「35年の幻覚剤の研究:長く奇妙なトリップ」と題された講演を行った。薬理学者の間で、世界的に有数の幻覚剤の専門家とみなされている。ニコルズの他の専門的な活動は、インディアナ州ウェストラファイエットのパデュー大学にて医薬化学と分子薬理学の教授であったことや、で医学生に講義することであった。 (ja) David Earl Nichols (born December 23, 1944, Covington, Kentucky) is an American pharmacologist and medicinal chemist. Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the method that is used to make the optical isomers of hallucinogenic amphetamines. His contributions include the synthesis and reporting of escaline, LSZ, 6-APB, 2C-I-NBOMe and other NBOMe variants (NBOMe-2C-B, NBOMe-2C-C, NBOMe-2C-D), and several others, as well as the coining of the term "entactogen". (en) |
| rdfs:label |
ديفيد إي. نيكولز (ar) David E. Nichols (en) David E. Nichols (fr) デヴィッド・アール・ニコルズ (ja) |
| owl:sameAs |
freebase:David E. Nichols yago-res:David E. Nichols http://d-nb.info/gnd/1159714991 http://viaf.org/viaf/51371836 https://orcid.org/0000-0002-1129-1697 wikidata:David E. Nichols dbpedia-ar:David E. Nichols dbpedia-fa:David E. Nichols dbpedia-fr:David E. Nichols dbpedia-ja:David E. Nichols https://global.dbpedia.org/id/2ntur |
| prov:wasDerivedFrom |
wikipedia-en:David_E._Nichols?oldid=1117250499&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:David_E._Nichols |
| foaf:name |
David Earl Nichols (en) |
| is dbo:wikiPageWikiLink of |
dbr:Psi-DOM dbr:Purdue_University_College_of_Pharmacy dbr:Entheogen dbr:Antitarget dbr:Rick_Strassman dbr:DOPF dbr:ETFELA dbr:Psychedelic_drug dbr:1-Aminomethyl-5-methoxyindane dbr:Lysergic_acid_2,4-dimethylazetidide dbr:Lysergic_acid_2-butyl_amide dbr:Lysergic_acid_3-pentyl_amide dbr:MBDB dbr:MDAI dbr:MDAT dbr:MDMA dbr:MDMAI dbr:MMAI dbr:Empathogen–entactogen dbr:David_Nichols dbr:2,5-Dimethoxy-4-iodoamphetamine dbr:2,5-Dimethoxy-4-trifluoromethylamphetamine dbr:6-Isopropyl-6-nor-lysergic_acid_diethylamide dbr:Bromo-DragonFLY dbr:Heffter_Research_Institute dbr:25I-NBMD dbr:25I-NBOMe dbr:2C-T dbr:2C-TFM dbr:2CBCB-NBOMe dbr:2CBFly-NBOMe dbr:3,4-Ethylidenedioxyamphetamine dbr:3-Methoxy-4-methylamphetamine dbr:4-Fluoro-5-methoxy-DMT dbr:4-HO-MPMI dbr:4-Methylthioamphetamine dbr:5-APDB dbr:5-IAI dbr:5-MeO-MPMI dbr:6-APDB dbr:6-Methyl-MDA dbr:Albert_Hofmann dbr:DMBMPP dbr:Escaline dbr:Nichols_(surname) dbr:History_of_entheogenic_drugs dbr:List_of_Equinox_episodes dbr:List_of_Purdue_University_alumni dbr:Hallucinogen dbr:Isoproscaline dbr:Terence_McKenna dbr:Jimscaline dbr:TCB-2 dbr:TFMFly dbr:Methylisopropyllysergamide dbr:O-Acetylpsilocin dbr:Neurons_to_Nirvana |
| is foaf:primaryTopic of |
wikipedia-en:David_E._Nichols |
